Skip to main content
SpringerLink
Log in

Definition, Biologie, Diagnostik und Therapie

Das CUP-Syndrom - Stand 2020

  • Zertifizierte Fortbildung
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3
4

© Alwin Krämer

5

Literatur

  1. Fizazi K et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v133-8

  2. Krämer A et al. Biologic Features of CUP. In: Krämer A, Löffler H (Hrsg.). Cancer of Unknown Primary. Springer International Publishing Switzerland, 2016

  3. Löffler H et al. [Cancer of unknown primary. Epidemiology and pathogenesis]. Radiologe. 2014;54(2):107-11

  4. Pentheroudakis G et al. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43(14):2026-36

  5. Bochtler T et al. Integrated clinico-molecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. Int J Cancer. 2020; https://doi.org/10.1002/ijc.32882

  6. Hemminki K et al. Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2012;23(7):1854-63

  7. van de Wouw AJ et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer. 2002;38(3):409-13

  8. Schroten-Loef C et al. Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012. Eur J Cancer. 2018;101:77-86

  9. Krämer A et al. Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions. J Clin Oncol. 2018;36(15_suppl):Abstr e24162

  10. Gatalica Z et al. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur J Cancer. 2018;94:179-86

  11. Varghese AM et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann Oncol. 2017;28(12):3015-21

  12. Löffler H et al. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget. 2016;7(28):44322-9

  13. Ross JS et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015;1(1):40-9

  14. Stenzinger A et al. [The role of pathology in the diagnostics of CUP syndrome]. Radiologe. 2014;54(2):124-33

  15. Dumur CI et al. Clinical verification of the performance of the pathwork tissue of origin test: utility and limitations. Am J Clin Pathol. 2011;136(6):924-33

  16. Monzon FA et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009;27(15):2503-8

  17. van Laar RK et al. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer. 2009;125(6):1390-7

  18. Tothill RW et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Rea. 2005;65(10):4031-40

  19. Handorf CR et al. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol. 2013;37(7):1067-75

  20. Kulkarni A et al. Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer. Diagn Pathol. 2012;7:110

  21. Weiss LM et al. Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn. 2013;15(2):263-9

  22. Greco FA et al. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst. 2013;105(11):782-90

  23. Seve P et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109(2):292-9

  24. Moller AK et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist. 2012;17(9):1146-54

  25. Roh JL et al. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol. 2009;45(3):218-24

  26. Reinert CP et al. Impact of PET/CT on clinical management in patients with cancer of unknown primary-a PET/CT registry study. Eur Radiol. 2020;30(3):1325-33

  27. Culine S et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21(18):3479-82

  28. Palmeri S et al. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: results of an Italian multicenter, randomized, phase II study. Cancer. 2006;107(12):2898-905

  29. Huebner G et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2009;100(1):44-9

  30. Hainsworth JD et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010;16(1):70-5

  31. Gross-Goupil M et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012; 48(5):721-7

  32. Hainsworth JD et al. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Cancer. 2015;121(10):1654-61

  33. Lee J et al. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Br J Cancer. 2013;108(1):39-48

  34. Valle JW et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 2009;101(4):621-7

  35. Hayashi H et al. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. J Clin Oncol. 2019;37(7):570-9

  36. Fizazi K et al. A phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary site (GEFCAPI 04). Ann Oncol. 2019;30(suppl_5):v851-v934

  37. Culine S et al. 5-fluorouracil and leucovorin as second-line chemotherapy in carcinomas of unknown primary site. Anticancer Res. 2001;21(2B):1455-7

  38. Hainsworth JD et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 2001;19(4):335-9

  39. Pouessel D et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res. 2003;23(3C):2801-4

  40. Hainsworth JD et al. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2005;104(9):1992-7

  41. Moller AK et al. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncol. 2010;49(4):431-5

  42. Hainsworth, JD et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116(10):2448-54

  43. Hainsworth JD et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007;25(13):747-52

  44. Bochtler T et al. Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity? Front Oncol. 2019;9:402

  45. Kolling S et al. "Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"? Front Oncol. 2019;9:1546

  46. Pentheroudakis G et al. Cancer of unknown primary site: missing primary or missing biology? Oncologist. 2007;12(4):418-25

  47. Gatalica Z et al. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget 2014;5(23):12440-7

  48. Tothill RW et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013;231(4):413-23

  49. Gay LM et al. Mutational burden of tumors with primary site unknown. J Clin Oncol. 2017;35(15_suppl):Abstr 3039

  50. Yarchoan M et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500-1

  51. Gröschel S et al. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud. 2016;2(6):a001180

  52. Palma NA et al. Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. Case Rep Oncol. 2014;7(2):503-8

  53. Tan DS et al. Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary. J Clin Oncol. 2013;31(14):e237-9

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik V, Universität Heidelberg, Heidelberg, Germany

    Maria Pouyiourou, Laura Claßen, Göran R. Boeckel, Tilmann Bochtler & Alwin Krämer

Authors
  1. Maria Pouyiourou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Claßen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Göran R. Boeckel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tilmann Bochtler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alwin Krämer
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Alwin Krämer und Tilmann Bochtler arbeiten als Studienonkologen für die von Roche gesponsorte Studie CUPISCO. Dabei werden ihrem Arbeitgeber der Aufwand der molekularen Tumorboards sowie studienbedingte Reisekosten erstattet. Alwin Krämer hat zudem finanzielle Unterstützung von BMS zur Durchführung der CheCUP Studie erhalten (IIT Studie).

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pouyiourou, M., Claßen, L., Boeckel, G. et al. Das CUP-Syndrom - Stand 2020. InFo Hämatol Onkol 23, 36–47 (2020). https://doi.org/10.1007/s15004-020-8068-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-020-8068-6

Search

Navigation